Trends to take away from the graphs:

-Out of the 3 treatment options that were of focus, the only treatment that performed better than the placebo is Capomulin. It not only increased the mice’s percentage of survival, but it also showed a reduction in the tumor size over the course of the 45 days.

-It seemed Infubinol could have been a promising runner-up candidate since the first graphs show delayed tumor growth as opposed to the placebo, but when you look at the percentages of survival after the 45 days, Infubinol performed worse than the placebo. The mice were better off having the tumor metastasize on its own rather than using this treatment option.

-Kapril performed roughly equally to the placebo group in almost every measure, meaning it is probably also ineffective as a treatment option.